9 research outputs found
Simultaneous description of four positive and four negative parity bands
The extended coherent state model is further extended in order to describe
two dipole bands of different parities. The formalism provides a consistent
description of eight rotational bands. A unified description for spherical,
transitional and deformed nuclei is possible. Projecting out the angular
momentum and parity from a sole state, the band acquires a
magnetic character, while the electric properties prevail for the other band.
Signatures for a static octupole deformation in some states of the dipole bands
are pointed out. Some properties which distinguish between the dipole band
states and states of the same parity but belonging to other bands are
mentioned. Interesting features concerning the decay properties of the two
bands are found. Numerical applications are made for Gd, Yb,
Th, Ra, U and Pu, and the results are
compared with the available data.Comment: 36 pages, 13 figures, 12 table
Algebraic nonlinear collective motion
Finite-dimensional Lie algebras of vector fields determine geometrical
collective models in quantum and classical physics. Every set of vector fields
on Euclidean space that generates the Lie algebra sl(3, R) and contains the
angular momentum algebra so(3) is determined. The subset of divergence-free
sl(3, R) vector fields is proven to be indexed by a real number . The
solution is the linear representation that corresponds to the
Riemann ellipsoidal model. The nonlinear group action on Euclidean space
transforms a certain family of deformed droplets among themselves. For positive
, the droplets have a neck that becomes more pronounced as
increases; for negative , the droplets contain a spherical bubble of
radius . The nonlinear vector field algebra is extended to
the nonlinear general collective motion algebra gcm(3) which includes the
inertia tensor. The quantum algebraic models of nonlinear nuclear collective
motion are given by irreducible unitary representations of the nonlinear gcm(3)
Lie algebra. These representations model fissioning isotopes () and
bubble and two-fluid nuclei ().Comment: 32pages, 4 figures not include
Edoxaban versus warfarin in patients with atrial fibrillation
Contains fulltext :
125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)